23andMe Holding Co. (ME)
NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 0.5582 |
| Open | 0.5500 |
| Bid | 0.5122 x 6700 |
| Ask | 0.5513 x 1400 |
| Day's range | 0.5400 - 0.5700 |
| 52-week range | 0.3500 - 2.1200 |
| Volume | |
| Avg. volume | 5,674,744 |
| Market cap | 267.288M |
| Beta (5Y monthly) | 1.24 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.4000 |
| Earnings date | 23 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 1.31 |
GlobeNewswireLargest study on the LRRK2 variant leads to discoveries about health, ancestry, and history
Findings from 23andMe research on Parkinson’s disease published in BrainThe LRRK2 variant is strongly associated with symptoms of Parkinson’s disease (PD) that are different from non-variant carriers with the diseaseThe study revealed novel findings of genetic “hotspots” in people from Mexico, Cuba, Puerto Rico, and Brazil, where the founder variant has sprung up in other communities23andMe has the largest LRRK2 G2019S research cohort, and launched the Parkinson’s Impact Project (PIP) in 2018 to
Simply Wall St.23andMe Holding Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags
23andMe Holding ( NASDAQ:ME ) Full Year 2024 Results Key Financial Results Revenue: US$219.6m (down 27% from FY 2023...
- Thomson Reuters StreetEvents
Q4 2024 23andMe Holding Co. Earnings Call
Q4 2024 23andMe Holding Co. Earnings Call
© 2024 Yahoo. All rights reserved.